Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

56%

5 trials in Phase 3/4

Results Transparency

0 of 7 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2

3(37.5%)

Phase 4

3(37.5%)

Phase 3

2(25.0%)

8Total

Phase 2(3)

Phase 4(3)

Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT07110038Phase 2Recruiting

DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile Carcinoma

Role: collaborator

NCT00565331Phase 2Completed

Rituximab for Prevention of Rejection After Renal Transplantation

Role: collaborator

NCT02570841Phase 4Completed

Pain Thresholds Under High-dose Topical Capsaicin

Role: collaborator

NCT00724022Phase 4Completed

Phase IV Study to Evaluate Calcineurin Inhibitor Reduced, Steroid Free Immunosuppression After Renal Transplantation

Role: collaborator

NCT00147381Phase 3Completed

Effectiveness and Safety of Campath in Combination With Tacrolimus Monotherapy to Prevent Kidney Graft Rejection

Role: collaborator

NCT00316810Phase 3Completed

Simultaneous Pancreas-kidney Transplantation With Campath Protocol

Role: collaborator

NCT01523951Completed

Topical Local Anaesthesia and Cooling During Capsaicin 8% Patch Application

Role: collaborator

NCT00912678Phase 4Completed

Minimizing Immunosuppression in Old for Old Kidney Transplantation

Role: collaborator

NCT00545493Phase 2Unknown

Efficacy of Tacrolimus and I.V.-Immunoglobulins in Rasmussen Encephalitis

Role: collaborator

All 9 trials loaded